title: A versatile, non genetically modified organism (GMO)-based strategy for controlling low-producer mutants in Bordetella pertussis cultures using antigenic modulation.
abstract: The uncontrolled presence of non-producer mutants negatively affects bioprocesses. In Bordetella pertussis cultures, avirulent mutants emerge spontaneously and accumulate. We characterized the dynamics of accumulation using high-throughput growth assays and competition experiments between virulent and avirulent (bvg(-) ) isolates. A fitness advantage of bvg(-) cells was identified as the main driver for bvg(-) accumulation under conditions of high virulence factor production. Conversely, under conditions that reduce their expression (antigenic modulation), bvg(-) takeover could be avoided. A control strategy was derived, which consists in applying modulating conditions whenever virulence factor production is not required. It has a wide range of applications, from routine laboratory operations to vaccine manufacturing, where pertussis toxin yields were increased 1.4-fold by performing early pre-culture steps in modulating conditions. Because it only requires subtle modifications of the culture medium and does not involve genetic modifications, this strategy is applicable to any B. pertussis isolate, and should facilitate regulatory acceptance of process changes for vaccine production. Strategies based on the same concept, could be derived for other industrially relevant micro-organisms. This study illustrates how a sound scientific understanding of physiological principles can be turned into a practical application for the bioprocess industry, in alignment with Quality by Design principles.
authors.affiliation: GSK Vaccines, Rixensart, Belgium. philippe.x.goffin@gmail.com.
authors.forename: Philippe
authors.initials: P
authors.lastname: Goffin
authors.affiliation: GSK Vaccines, Rixensart, Belgium.
authors.forename: Thomas
authors.initials: T
authors.lastname: Slock
authors.affiliation: GSK Vaccines, Rixensart, Belgium.
authors.forename: Vincent
authors.initials: V
authors.lastname: Smessaert
authors.affiliation: GSK Vaccines, Rixensart, Belgium.
authors.forename: Philippe
authors.initials: P
authors.lastname: De Rop
authors.affiliation: GSK Vaccines, Rixensart, Belgium.
authors.forename: Philippe
authors.initials: P
authors.lastname: Dehottay
mesh_terms: D016525:Antigenic Modulation / Q000235:genetics*; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism*; D001886:Bordetella pertussis / Q000235:genetics / Q000378:metabolism*; D060847:Metabolic Engineering / Q000379:methods*; D008954:Models, Biological; D009154:Mutation / Q000235:genetics*; D009525:Niacin / Q000378:metabolism; D010566:Virulence Factors, Bordetella / Q000032:analysis / Q000235:genetics / Q000378:metabolism*
chemical_list: D001426:Bacterial Proteins; D010566:Virulence Factors, Bordetella; D009525:Niacin
keywords: Antigenic modulation; Bordetella pertussis; Mutant control strategy; Phase variation; bvg (Bordetella virulence gene)